Welcome to our dedicated page for CME Group SEC filings (Ticker: CME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CME Group Inc. (CME) SEC filings page on Stock Titan brings together the company’s regulatory disclosures as a publicly traded operator in the securities and commodity exchanges industry. CME Group files a range of documents with the U.S. Securities and Exchange Commission, including current reports on Form 8-K that provide updates on financial results, corporate events and governance matters.
Recent Form 8-K filings illustrate how CME Group uses SEC reports to communicate with investors. One 8-K describes the release of quarterly financial results, including the use of non-GAAP measures such as non-GAAP revenues, expenses, operating income, net income and earnings per share, together with reconciliations to the most comparable GAAP figures. Another 8-K reports a jury verdict in favor of CME Group and the Board of Trade of the City of Chicago, Inc. in a class action involving certain Class B shareholders and members. A further 8-K discloses the planned retirement of the company’s Chief Accounting Officer and outlines the transition process.
In addition to 8-Ks, CME Group’s SEC reporting framework includes annual and quarterly reports, proxy statements and other filings that address topics such as results of operations, financial condition, risk factors, corporate governance and compensation. These documents help investors understand the company’s role as a derivatives marketplace offering futures, options, cash and OTC trading across interest rates, equity indexes, foreign exchange, energy, agricultural products, metals and cryptocurrencies, as well as its operation of CME Clearing and electronic platforms like CME Globex, BrokerTec and EBS.
On Stock Titan, CME filings are supplemented with AI-powered summaries designed to explain the key points of lengthy documents, such as 10-K and 10-Q reports, in accessible language. Users can quickly identify major themes, while still having access to the full text of each filing. The page also provides visibility into event-driven filings like Form 8-K, which can include announcements about earnings releases, legal outcomes, executive changes and other material developments.
CME Group Inc. filed a current report to furnish its earnings press release for the quarter and year ended December 31, 2025. The press release, dated February 4, 2026, is attached as Exhibit 99.1 and outlines the company’s financial results.
The release includes several non-GAAP financial measures, such as adjusted revenues, expenses, operating income, net income and earnings per share. Management states these are intended to supplement GAAP results and improve comparability with prior periods, and provides reconciliations to the most directly comparable GAAP figures in accordance with Regulation G.
CME Group Inc. filed an 8-K to note that on February 2, 2026 it communicated pricing changes to its clients through Special Executive Report 9676. The company states that a copy of this pricing notice has been posted to its website.
The disclosure is furnished under Item 7.01, meaning it is treated as information provided for Regulation FD purposes. CME Group clarifies that this information is not deemed “filed” under Section 18 of the Exchange Act and is not incorporated into other securities law filings unless specifically referenced.
CME Group Inc. reported that its Chairman and CEO Terrence A. Duffy, who is also a director, sold 25,000 shares of Class A common stock on December 11, 2025.
The sale was executed in two trades: 13,809 shares at prices ranging from $268.66 to $269.66 per share and 11,911 shares at prices ranging from $269.68 to $270.51 per share, with prices within each $1 range aggregated and reported on a weighted-average basis. After these transactions, Duffy directly beneficially owned 65,804 Class A shares.
CME Group Inc. officer Derek Louis Sammann, Senior Managing Director and Global Head of Commodities Markets, reported several transactions in CME Class A common stock. On November 6, 2025, he transferred 2,300 shares at a stated price of $0, reducing his direct holdings to 8,683 shares and increasing the holdings of his revocable living trust to 16,914 shares, reflecting an internal ownership reorganization.
On November 20, 2025, the trust sold 5,886 shares at $275.65 per share, leaving the trust with 11,028 shares. On the same date, Sammann’s spouse sold 1,314 shares at $275.74 per share, leaving 7,022 shares held by the spouse. These trades update disclosed indirect ownership positions through both the trust and spouse.
CME Group (CME) insider transaction: Officer Hilda Harris Piell, Sr MD & Chief HR Officer, reported a Code G gift of 973 Class A common shares on 11/07/2025 at a reported price of $0. Following the transaction, she beneficially owns 29,418 shares, held directly.
The filing notes the shares were gifted to her donor advised fund. This is a charitable transfer rather than a market sale.
CME Group Inc. (CME) reported an insider transaction: Director Harold Ford Jr. sold 1,000 Class A shares on November 3, 2025, coded S (open market sale). The weighted average sale price was $263.53, with a price range of $263.21–$263.68.
Following the sale, he directly owns 1,091 shares. The company notes prices within a $1 range were aggregated and maintains detailed records available upon request.
CME Group Inc. reported Q3 2025 results with total revenue of
Market data and information services grew to
Year‑to‑date, operating cash flow reached
CME Group Inc. furnished an 8-K announcing quarterly results. The company reported that a press release dated October 22, 2025, covering financial results for the quarter ended September 30, 2025, was furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition).
The press release includes non-GAAP measures—revenues, expenses, operating income, net income, and earnings per share—with reconciliations to the most comparable GAAP metrics pursuant to Regulation G. The Item 2.02 information, including the exhibit, is furnished and not deemed filed under Section 18 of the Exchange Act.
Jonathan L. Marcus, Senior Managing Director and General Counsel at CME Group Inc. (CME), reported a sale of 392 shares of Class A common stock on 09/18/2025 at a reported price of $262 per share. The filing shows the transaction was executed under a Rule 10b5-1 trading plan adopted on February 18, 2025. After this sale the reporting person beneficially owns 7,851 shares of Class A common stock. The Form 4 is singularly filed for one reporting person and was signed by Margaret Austin Wright on behalf of Jonathan L. Marcus.
Form 144 notice for CME Group Inc. (CME) shows a proposed sale of 392 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $102,704.00 and an approximate sale date of 09/18/2025 on NASDAQ. The securities were acquired from the issuer as restricted stock on 09/16/2025 and payment was recorded as 09/16/2025. The filing also reports prior transactions: the person for whose account the sale is filed sold 376 shares on 09/16/2025 for gross proceeds of $97,368.96. The filing includes the required representation that the signer does not possess undisclosed material adverse information.